Cell and Gene Therapy Catapult Appoints Board Members
This article was originally published in Scrip
The UK organization Cell and Gene Therapy Catapult has appointed new non-executive directors Fiona Watt, Susan Foden and Steven Chatfield to its board. Watt has spent 20 years at the CRUK London Research Institute and helped establish the CRUK Cambridge Research Institute and Wellcome Trust Centre for stem cell research in Cambridge. Foden has been a non-executive director for various life science companies and currently holds non-executive positions at companies including British Technology Group plc., Vectura plc., Evgen Pharma plc and BerGenBio AS. Chatfield brings over 35 years' experience and previously held executive positions at the Health Protection Agency, Emergent BioSolutions, Microscience Ltd, Medeva plc, Evans Medical and Wellcome Biotechnology.